Ipilimumab: beside a new treatment under test
229 studies: a new drug, cell therapy or vaccine is what the study tests. Page 1 of 3. Open to participants first (43), then studies with results posted, then the rest; newest registration first within each.
- A Multicenter Study Evaluating the Efficacy and Safety of Nivolumab and Ipilimumab in Combination With NP-101 Versus Placebo in Refractory Advanced and Metastatic Gastroenteropancreatic Neuroendocrine Carcinomas (GEP-NECs)Not yet recruitingNCT07935928Phase 2/3Report a problem
- iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable MelanomaNot yet recruitingNCT07815574Phase 3Report a problem
- Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 TherapyNot yet recruitingNCT07762716Phase 1/2Report a problem
- Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 TherapyNot yet recruitingNCT07762703Phase 1/2Report a problem
- Gut Microbiota Modulation for Immunotherapy Resensitization in Advanced Renal Cell CarcinomaRecruitingNCT07611825Phase 2Report a problem
- A 2-part Phase 1/2 Open-label Trial on ODM-212RecruitingNCT07563738Phase 1/2Report a problem
- A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor CancerRecruitingNCT07532902Phase 1Report a problem
- PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable MelanomaNot yet recruitingNCT07511036Phase 2Report a problem
- VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell CarcinomaRecruitingNCT07510334Phase 2Report a problem
- A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)RecruitingNCT07430202Phase 1Report a problem
- A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)RecruitingNCT07401875Phase 1Report a problem
- Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney CancerRecruitingNCT07383441Phase 3Report a problem
- A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)RecruitingNCT07293351Phase 1/2Report a problem
- A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)RecruitingNCT07291076Phase 1/2Report a problem
- Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell CancerRecruitingNCT07227415Phase 1/2Report a problem
- Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.RecruitingNCT07227012Phase 1/2Report a problem
- A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)RecruitingNCT07195682Phase 1Report a problem
- Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell CancerRecruitingNCT07128680Phase 1Report a problem
- NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic CancerRecruitingNCT06941857Phase 2Report a problem
- SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)RecruitingNCT06889493Phase 1Report a problem
- Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON TrialRecruitingNCT06866262Phase 1/2Report a problem
- MAQ-001 in Patients With Advanced Solid TumorsRecruitingNCT06514651Phase 1Report a problem
- CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney CancerRecruitingNCT06399419Phase 1Report a problem
- A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab MonotherapyRecruitingNCT06362369Phase 1/2Report a problem
- XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic CancerRecruitingNCT06353646Not applicableReport a problem
- NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 TrialRecruitingNCT06342037Phase 2Report a problem
- Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast CancerRecruitingNCT06324240Phase 1Report a problem
- Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisRecruitingNCT06047379Phase 1/2Report a problem
- Combination of CAR-DC Vaccine and ICIs in Malignant TumorsRecruitingNCT05631886Phase 1Report a problem
- A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid TumorsRecruitingNCT05584670Phase 1/2Report a problem
- A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid TumorsRecruitingNCT05536141Phase 1Report a problem
- Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid TumorsRecruitingNCT05533697Phase 1/2Report a problem
- Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in MelanomaRecruitingNCT05498792Early Phase 1Report a problem
- KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLCRecruitingNCT05254184Phase 1Report a problem
- Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsRecruitingNCT05176483Phase 1Report a problem
- Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICIRecruitingNCT04954599Phase 1/2Report a problem
- Intralesional Influenza Vaccine for the Treatment of Stage I-IV MelanomaRecruitingNCT04697576Phase 1Report a problem
- Study to Evaluate VT3989 in Patients With Metastatic Solid TumorsRecruitingNCT04665206Phase 1/2Report a problem
- DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular CarcinomaRecruitingNCT04248569Phase 1Report a problem
- Pan Tumor Rollover StudyRecruitingNCT03899155Phase 2Report a problem
- Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma PatientsRecruitingNCT03166397Phase 2Report a problem
- A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaRecruitingNCT03017820Phase 1Report a problem
- Cytokine-induced Killer Study for Patients With Stage II MelanomaNot yet recruitingNCT02498756Phase 2Report a problem
- Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2TerminatedNCT06790303Phase 2Results postedReport a problem
- A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid TumorsCompletedNCT05407675Phase 1/2Results postedReport a problem
- Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic CancerCompletedNCT05014776Phase 2Results postedReport a problem
- A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung CancerCompletedNCT05005273Phase 2Results postedReport a problem
- Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain MetsTerminatedNCT04899921Phase 2Results postedReport a problem
- FLX475 in Combination With Ipilimumab in Advanced MelanomaTerminatedNCT04894994Phase 2Results postedReport a problem
- Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent StudyCompletedNCT04887870Phase 2/3Results postedReport a problem
- Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant MesotheliomaTerminatedNCT04840615Phase 1Results postedReport a problem
- UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of MelanomaCompletedNCT04382664Phase 2Results postedReport a problem
- Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid TumorsTerminatedNCT04319224Phase 1/2Results postedReport a problem
- Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory MelanomaTerminatedNCT04093323Phase 2Results postedReport a problem
- BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver CancersCompletedNCT04021043Phase 1/2Results postedReport a problem
- PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid TumorsTerminatedNCT03993379Phase 2Results postedReport a problem
- IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for MelanomaTerminatedNCT03958383Phase 1/2Results postedReport a problem
- Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)CompletedNCT03739710Phase 2Results postedReport a problem
- A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced MelanomaCompletedNCT03711188Phase 2Results postedReport a problem
- A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung CancerCompletedNCT03575793Phase 1/2Results postedReport a problem
- Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell CarcinomaTerminatedNCT03552380Phase 2Results postedReport a problem
- REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung CancerTerminatedNCT03515629Phase 3Results postedReport a problem
- An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have SpreadCompletedNCT03459222Phase 1/2Results postedReport a problem
- A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory MelanomaTerminatedNCT03445533Phase 3Results postedReport a problem
- A Study of REGN2810 and Ipilimumab in Patients With Lung CancerTerminatedNCT03430063Phase 2Results postedReport a problem
- Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung CancerCompletedNCT03409614Phase 3Results postedReport a problem
- Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)TerminatedNCT03406715Phase 2Results postedReport a problem
- A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced CancersCompletedNCT03400332Phase 1/2Results postedReport a problem
- Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory CancersCompletedNCT03388632Phase 1Results postedReport a problem
- A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)TerminatedNCT03347123Phase 1/2Results postedReport a problem
- Adoptive Cell Therapy Across Cancer DiagnosesCompletedNCT03296137Phase 1/2Results postedReport a problem
- TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian CancerCompletedNCT03287674Phase 1/2Results postedReport a problem
- Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS MutationCompletedNCT03271047Phase 2Results postedReport a problem
- A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid TumorsTerminatedNCT03251924Phase 1/2Results postedReport a problem
- A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic MalignanciesCompletedNCT03241173Phase 1/2Results postedReport a problem
- Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic CancerCompletedNCT03190265Phase 2Results postedReport a problem
- Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic MalignanciesCompletedNCT03126110Phase 1/2Results postedReport a problem
- A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6CompletedNCT03058289Phase 1/2Results postedReport a problem
- A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung CancerTerminatedNCT03026166Phase 1/2Results postedReport a problem
- PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or LymphomasTerminatedNCT03013491Phase 1/2Results postedReport a problem
- Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable CancerTerminatedNCT03009058Phase 1/2Results postedReport a problem
- A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid TumorsCompletedNCT02983045Phase 1/2Results postedReport a problem
- A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid TumorsCompletedNCT02913313Phase 1/2Results postedReport a problem
- JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid TumorsCompletedNCT02904226Phase 1/2Results postedReport a problem
- An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have SpreadCompletedNCT02737475Phase 1/2Results postedReport a problem
- An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have SpreadCompletedNCT02658890Phase 1/2Results postedReport a problem
- A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic MelanomaCompletedNCT02644967Phase 2Results postedReport a problem
- A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With MelanomaTerminatedNCT02385669Phase 1/2Results postedReport a problem
- Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLCActive, not recruitingNCT02259621Phase 2Results postedReport a problem
- RTA 408 Capsules in Patients With Melanoma - REVEALCompletedNCT02259231Phase 1/2Results postedReport a problem
- A Phase I/II Study of Intratumoral Injection of SD-101CompletedNCT02254772Phase 1/2Results postedReport a problem
- Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)CompletedNCT02231749Phase 3Results postedReport a problem
- Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic MelanomaCompletedNCT02073123Phase 1/2Results postedReport a problem
- A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadCompletedNCT02060188Phase 2Results postedReport a problem
- Immunotherapy Study for Patients With Stage IV MelanomaTerminatedNCT02054520Phase 2Results postedReport a problem
- A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)CompletedNCT02039674Phase 1/2Results postedReport a problem
- Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV MelanomaCompletedNCT02032810Phase 1Results postedReport a problem
- CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic MelanomaCompletedNCT02027935Phase 2Results postedReport a problem
- A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma PatientsCompletedNCT02017717Phase 3Results postedReport a problem
- A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid TumorsCompletedNCT01928394Phase 1/2Results postedReport a problem